Figure 2: Shielding effect and the MFCC scheme showing eight distinct fragment systems employed in the present study: (A) etilclopride, analyzed residue and shielding residue with conjugated caps; (B) analyzed residue and shielding residue with conjugated caps; (C) eticlopride plus conjugated caps; (D) conjugated caps only; (E) eticlopride plus shielding amino acid residue with conjugated caps; (F) shielding residue with conjugated caps; (G) eticlopride plus conjugated caps; (H) conjugated caps only; (I) representative image of shielding effect of Val111 over Ser165 interaction with eticlopride. Eticlopride, analyzed residue, shielding residue and caps are represented as M, Ri, Rb and C, respectively.